Takeda Invests Rp539 Billion in Indonesia's Plasma Ecosystem

Japanese biopharmaceutical company Takeda has committed to investing US$30 million, or approximately Rp539 billion, to build a plasma bank network in Indonesia. The initial phase, spanning two years, is intended to serve as the foundation for developing a national plasma-derived medicinal products (PODP) industry.

Minister of Investment and Downstreaming, Rosan Roeslani, stated that the investment demonstrates strong global investor confidence in Indonesia’s high-tech healthcare sector. He noted that the strategic investment is expected to bring positive impacts through technology transfer, human resource development, and the creation of high-skilled employment.

“The government continues to encourage investment that provides added value and strengthens national industrial capacity so that Indonesia can become a manufacturing and innovation hub for healthcare in the region,” Rosan said.

The collaboration also reinforces the national economic transformation agenda through downstreaming in the health sector to enhance global competitiveness. Japan remains a crucial investment partner for Indonesia, with realised investment in the first quarter of 2026 ranking fifth at US$1 billion. Cumulatively, from 2021 to the first quarter of 2026, total Japanese investment reached US$18.1 billion, growing at an average rate of 13.2 percent and absorbing 299,460 workers.

Through this strategic partnership, the government is optimistic that public access to plasma-derived medicinal products will increase, fostering an innovative biopharmaceutical industry. The first plasma bank is targeted to commence operations in 2027 as part of the development of a national plasma network that meets international standards.